- Trials with a EudraCT protocol (130)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
130 result(s) found for: Neurotoxicity.
Displaying page 1 of 7.
| EudraCT Number: 2012-000398-21 | Sponsor Protocol Number: ESTEVE-SIGM-202 | Start Date*: 2012-06-21 | |||||||||||
| Sponsor Name:Laboratorios del Dr. Esteve, S.A. | |||||||||||||
| Full Title: A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence a... | |||||||||||||
| Medical condition: OXL-induced chronic neuropathy. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002576-27 | Sponsor Protocol Number: ICM-URC2016/27 | Start Date*: 2017-03-01 | |||||||||||
| Sponsor Name:Institut régional du Cancer de Montpellier | |||||||||||||
| Full Title: Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter ... | |||||||||||||
| Medical condition: colon cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002767-26 | Sponsor Protocol Number: LyRICX | Start Date*: 2019-06-25 |
| Sponsor Name:Academic Medical Center | ||
| Full Title: Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) | ||
| Medical condition: gastroesophageal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001333-88 | Sponsor Protocol Number: ACTION | Start Date*: 2014-10-16 |
| Sponsor Name:Academic Medical Center | ||
| Full Title: A phase Ib/II study on the addition of Nab-paclitaxel (Abraxane) to capecitabine and oxaliplatin in the first-line treatment of metastastasized oesophagogastric carcinoma | ||
| Medical condition: Metastasized oesophagogastric carcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-002361-36 | Sponsor Protocol Number: ONCOSUR-2012-01 | Start Date*: 2012-10-17 | |||||||||||
| Sponsor Name:ONCOSUR | |||||||||||||
| Full Title: Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. | |||||||||||||
| Medical condition: Metastatic HER2-negative breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-004772-12 | Sponsor Protocol Number: NLGPCNSL | Start Date*: 2006-12-19 | |||||||||||
| Sponsor Name:Nordic Lymphoma Group | |||||||||||||
| Full Title: Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by... | |||||||||||||
| Medical condition: Newly diagnosed Primary Central Nervous Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) SE (Completed) FI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001287-75 | Sponsor Protocol Number: CPP-340 | Start Date*: 2007-06-11 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:CENTRE PAUL PAPIN - IRCAM | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: Proteomic and genetic analysis of neurotoxicity predicting markers in oxaliplatine treated patients with colorectal carcinoma. | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Colorectal cancer patients undergoing treatment with oxaliplatine every 15 days, 5 fluoro uracile and calcium levofolinate, for adjuvant or metastatic setting will be recruited in this study. T... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-000784-33 | Sponsor Protocol Number: TacTremorConversion | Start Date*: 2017-07-31 | |||||||||||
| Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
| Full Title: Effect of Envarsus conversion on tacrolimus-associated tremor in renal transplant patients. An open-label, single centre, prospective pharmacodynamic/pharmacokinetic clinical study | |||||||||||||
| Medical condition: Tacrolimus-associated tremor | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-002187-32 | Sponsor Protocol Number: DMSG03/14 | Start Date*: 2014-09-05 |
| Sponsor Name:Danish Myeloma Study Group | ||
| Full Title: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagno... | ||
| Medical condition: multiple myeloma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004172-30 | Sponsor Protocol Number: PREPARE | Start Date*: 2021-10-13 |
| Sponsor Name:Charité – Universitätsmedizin Berlin | ||
| Full Title: Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemothe... | ||
| Medical condition: Breast cancer patients scheduled for treatment with paclitaxel chemotherapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-000767-28 | Sponsor Protocol Number: 20061 | Start Date*: 2006-09-29 |
| Sponsor Name:Vienna Medical University | ||
| Full Title: Standardisierte Verlaufsbeobachtung von Patienten mit intrathekalem S(+)-Ketamin | ||
| Medical condition: Intrathecal S(+)-ketamine is a potent option in the treatment of chronic severe neuropathic pain in cancer patients refractory to conventional therapeutic strategies (Benrath et al. 2005). However,... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-005508-37 | Sponsor Protocol Number: PI2021_843_0197 | Start Date*: 2021-12-20 |
| Sponsor Name:CHU Amiens-Picardie | ||
| Full Title: Evaluation of plasma concentrations of intravenous lidocaine and epidural ropivacaine when used in combination in major abdominal surgery | ||
| Medical condition: major abdominal surgery | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-019587-36 | Sponsor Protocol Number: DSHNHL2009-1 | Start Date*: 2011-10-10 | |||||||||||
| Sponsor Name:Universität des Saarlandes | |||||||||||||
| Full Title: Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventiona... | |||||||||||||
| Medical condition: Diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-003116-12 | Sponsor Protocol Number: IELSG45 | Start Date*: 2019-11-01 | |||||||||||
| Sponsor Name:International Extranodal Lymphoma Study Group - IELSG | |||||||||||||
| Full Title: RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial) | |||||||||||||
| Medical condition: Patients with newly diagnosed primary central nervous system lymphoma with age ≥70 years old | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) FI (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-003894-18 | Sponsor Protocol Number: M07CCL | Start Date*: 2008-01-30 |
| Sponsor Name:NKI-AVL | ||
| Full Title: Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma | ||
| Medical condition: Non-small cell lung cancer locally advanced | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-005635-10 | Sponsor Protocol Number: ATEGE_LIVER | Start Date*: 2006-05-22 |
| Sponsor Name:Liver Unit, ICMD, Hospital Clinic Barcelona | ||
| Full Title: INDUCTION TREATMENT FOLLOWED BY IMMUNOSUPPRESSION WITHDRAWAL IN LIVER TRANSPLANTATION: A COMPARATIVE TRIAL. Tratamiento de inducción y retirada de la inmunosupresión en el trasplante hepático. Estu... | ||
| Medical condition: Liver transplantation | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000286-36 | Sponsor Protocol Number: IGR2012/1950 | Start Date*: 2014-04-02 |
| Sponsor Name:Gustave Roussy | ||
| Full Title: A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors | ||
| Medical condition: patients with pre-treated metastatic and /or primary mediastinal non-seminomatous germ-cell tumors | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-002787-95 | Sponsor Protocol Number: WP-07-148 | Start Date*: 2008-01-03 | |||||||||||
| Sponsor Name:Department of Pulmonology, Rijnstate Hospital | |||||||||||||
| Full Title: A randomized double-blind study of N-Acetylcysteine vs. placebo to Prevent Neurotoxicity induced by Platinum containing chemotherapy in patients treated for (Non)Small Cell Lung Cancer and Malignan... | |||||||||||||
| Medical condition: Cisplatin-induced peripheral neuropathy will be investigated. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-004508-35 | Sponsor Protocol Number: 2680 | Start Date*: 2005-12-14 |
| Sponsor Name:Royal Marsden Hospital | ||
| Full Title: THE USE OF PET/CT SCANNING TO ASSESS EARLY RESPONDERS TO TARCEVA (ERLOTINIB): A PHASE II STUDY | ||
| Medical condition: Advanced non-small cell lung cancer (NSCLC) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-006871-60 | Sponsor Protocol Number: DIRECTOR | Start Date*: 2009-06-23 | |||||||||||
| Sponsor Name:University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg | |||||||||||||
| Full Title: Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma | |||||||||||||
| Medical condition: progressive or recurrent glioblastoma after first surgery for glioblastoma and after completion of radiotherapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.